Patents by Inventor Christopher A. O'Callaghan

Christopher A. O'Callaghan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective Inhibitors Of i-NOS For Use Against Viral Infection
    Publication number: 20180214430
    Abstract: The present invention concerns compounds for use in the prevention of viral replication and/or the prevention or treatment of a viral infection, wherein the compounds are selective inhibitors of inducible nitric oxide synthase, and methods of preventing viral replication and/or preventing or treating viral infections in a subject comprising administering a prophylactically or therapeutically effective amount of the compounds.
    Type: Application
    Filed: July 15, 2016
    Publication date: August 2, 2018
    Applicant: UCL Business PLC
    Inventors: Christopher O'Callaghan, Claire Smith, Angrew Easton
  • HLA-E BINDING
    Publication number: 20150361180
    Abstract: The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.
    Type: Application
    Filed: April 10, 2015
    Publication date: December 17, 2015
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Veronique M. Braud, David S.J. Allan, Graham S. Ogg, Christopher A. O'Callaghan, Andrew J. McMichael
  • HLA-E BINDING
    Publication number: 20080274475
    Abstract: The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.
    Type: Application
    Filed: April 25, 2008
    Publication date: November 6, 2008
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Veronique M. Braud, David S.J. Allan, Graham S. Ogg, Christopher A. O'Callaghan, Andrew J. McMichael
  • HLA-E binding
    Patent number: 7410767
    Abstract: The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: August 12, 2008
    Assignee: Isis Innovation Limited
    Inventors: Veronique M. Braud, David S. J. Allan, Graham S. Ogg, Christopher A. O'Callaghan, Andrew J. McMichael